Patent
Divalent-metal coated nanoparticles for delivery of compositions into the central nervous system by nasal insufflation
Juan Sanchez-Ramos,Vasyl Sava,Shijie Song,Shyam S. Mohapatra,Subhra Mohapatra +4 more
- 14 Sep 2012
7
TL;DR: In this article, the divalent metal transporter expressed on olfactory nerve terminals to transport divalent cationcoated or cation-containing nanoparticles to all regions of brain was examined.
read more
Abstract: The compositions and methods of the disclosure particularly target the divalent metal transporter expressed on olfactory nerve terminals to transport divalent cation-coated or cation- containing nanoparticles to all regions of brain. It has been found that such divalent cation- containing nanoparticles, including those nanoparticles comprising manganese have affinity for the metal transport receptor proteins. Although this receptor has particular affinity for manganese, it is contemplated that other divalent ions, including magnesium, calcium, and the like may also be bound to such receptors leading to transport of the nanoparticles into the intracellular cytoplasm. Nanoparticles have been developed, therefore, as vehicles for parenteral delivery of genes, proteins and drugs. The present disclosure encompasses embodiments of nanoparticle-based compositions and methods for the use thereof for the delivery of genes, oligonucleotides, including but not limited to small interfering RNA, and other small molecule drugs, into the brain by nasal insufflation.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Patent
Biodegradable and clinically-compatible nanoparticles as drug delivery carriers
Chiang J. Li,Youzhi Li,Keyur Gada,Xiaoshu Dai +3 more
- 05 Feb 2014
TL;DR: In this paper, the composition of a nanoparticle based on a magnesium salt, and methods of drug delivery using the nanoparticle were discussed, and a preferred embodiment uses magnesium phosphate, with or without a shell to deliver aiRNA and/or siRNA.
4
Patent
Compositions Containing a Biologically Active Material and a Non-Ordered Inorganic Oxide Material and Methods of Making and Using the Same
Cristian Libanati,Michiel Van Speybroeck,Fred Monsuur +2 more
- 13 Nov 2013
TL;DR: In this article, the methods of making and using compositions containing a biologically active material and a non-ordered inorganic oxide material are also disclosed, as well as methods of combining biologically active and inorganic materials.
1
Patent
Composition for gene therapy of the central nervous system, process of production and use thereof
Roselena Silvestri Schuh,Ferreira Teixeira Helder,Guilherme Baldo,Ursula da Silveira Matte,Roberto Giugliani,Juliana Bidone +5 more
- 07 Feb 2019
TL;DR: In this paper, a composition for gene therapy of the central nervous system comprising non-viral carriers of nanometric size (1.0 micrometer) complexed with at least one nucleic acid for purposes of gene therapy via nasal administration was described.
Patent
Graphene oxide nanoparticle compositions and methods of making the same
Sabyasachi Sarkar,Arsheen Allam,Afreen Allam,Abdul Allam +3 more
- 29 Sep 2016
TL;DR: Water soluble graphene oxide nanoparticles (GO) as mentioned in this paper have been shown to cross the blood brain barrier in a mouse model of vascular dementia, and methods for reversible encapsulation of a molecule within water soluble carbon nanoparticles including the GO nanoparticles are provided that allow for delivery of the wsCNP loaded with therapeutic and/or imaging agents to a subject in need by releasing the therapeutic/imaging agent upon an increase in pH above about 7.2.
References
Nanoparticles for direct nose-to-brain delivery of drugs.
TL;DR: The evidence for the existence of a direct nose-to-brain delivery route for nanoparticles administered to the nasal cavity and transported via the olfactory epithelium and/or via the trigeminal nerves directly to the CNS is evaluated.
702
Chitosan nanoparticles for oral drug and gene delivery.
Katherine Bowman,Kam W. Leong +1 more
TL;DR: A review of studies on the formulation and oral delivery of chitosan nanoparticles shows their efficacy in enhancing drug uptake and promoting gene expression, and highlights the potential of the polymer as a component of oral delivery systems.
475
Patent
Nanoparticles for protein drug delivery
Hsing-Wen Sung,Mei Chin Chen,Yu Hsin Lin,Hsiang-Fa Liang,Hosheng Tu +4 more
- 02 Feb 2009
TL;DR: In this paper, the authors reveal the nanoparticles composed of chitosan, poly-glutamic acid, and at least one protein drug or bioactive agent characterized with a positive surface charge and their enhanced permeability for paracellular protein drug and bio-active agent delivery.
187
Patent
Analgesics for nasal administration
P.J. Birch,Ann G. Hayes,Peter James Watts,Jonathan Castile +3 more
- 19 Mar 2003
TL;DR: In this article, an analgesic and a delivery agent are combined in a pharmaceutical composition such that, on introduction into the nasal cavity of a patient to be treated, the analgesic may be delivered to the bloodstream to produce within 30 minutes a therapeutic plasma concentration, Cther, of 0.2 ng/ml or greater which is maintained for a duration Tmaint of at least 2 hours.
28
Patent
Mucoadhesive nanocomposite delivery system
Yoon Jeong Park,Arthur Yang,Allan E. David,Ruiyun Zhang +3 more
- 20 May 2005
TL;DR: A nanocomposite delivery system uses chitosan as a mucoadhesive material encapsulated in a surface modified network of colloidal nanoporous nanoparticles, such as silica, or other colloid-forming materials, especially metal oxides as discussed by the authors.
19